News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Backs Seattle Genetics, Inc. (SGEN) Lymphoma Drug Adcetris


7/14/2011 10:53:54 AM

A federal advisory panel backed the approval of a Seattle Genetics Inc. (SGEN) experimental drug as a Hodgkin lymphoma treatment. The drug, which has a generic name of brentuximab vodotin and a proposed brand name of Adcetris, is currently under review by the U.S. Food and Drug Administration for two types of lymphoma that have not responded to other treatments; Hodgkin lymphoma and anaplastic large cell lymphoma. A panel of non-FDA medical experts is discussing Adcetris at a meeting Thursday.

Read at Wall Street Journal
Read at Seattle Times
Read at Xconomy

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES